Should you buy Biogen stock? (NasdaqGS:BIIB). Let's see how it does in our automated value investing analysis system.
Based on historical returns, we believe that Biogen can grow its free cash at a rate of about 3%. That's positive!
(Biogen stock price per share)
||BIIB Fair Price
(based on intrinsic value)
||BIIB Safety Price (based on a variable margin of safety)||$144.26|
||PE Ratio versus Sector||10% higher than other Healthcare stocks|
|PE Ratio versus Industry||61% lower than other Biotechnology stocks|
|Free Cash Flow Jitter||30%|
We believe that Biogen may be worth examining further. It's making money, which is a very positive sign. Is it on sale?
Biogen looks overpriced right now. If you're looking for a bargain in the stock market, you should probably look elsewhere for a great deal. This might still be a great stock to own—but it's not on sale right now.
Does Biogen have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.
Most Popular Articles